Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.63 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.54 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.51 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13859302 | 0.90 | SRC (0.53) | BRD4ALKROCK1ALDH1A1MAPT | |
| SCHEMBL263688 | 0.83 | JAK2 (0.48) | BRD4ALKMAPKAPK2 | |
| SCHEMBL263109 | 0.83 | JAK2 (0.51) | BRD4ALKAURKA | |
| SCHEMBL265214 | 0.80 | BRD4 (0.49) | BRD4ALKALDH1A1MAPT | |
| SCHEMBL264498 | 0.79 | BRD4 (0.48) | BRD4ALKALDH1A1MAPT | |
| SCHEMBL264535 | 0.78 | KCNA5 (0.50) | BRD4ALKALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL263808 | 0.78 | BRD4 (0.49) | BRD4ALK | |
| SCHEMBL263544 | 0.78 | DHFR (0.44) | BRD4 | |
| SCHEMBL6313126 | 0.77 | HTR3A (0.52) | ALKMAPKAPK2METMAPTEGFR | |
| SCHEMBL270815 | 0.77 | BRD4 (1.00) | BRD4ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | BRD4 142/4885ALK 154/4885MAPKAPK2 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.